Full Review Deadlines

Deadline = two weeks prior to the monthly IRB meeting at which you would like your project reviewed. The meeting is typically held the second Monday of each month.

Deadline = Two weeks before monthly Board meeting at which the research must be reviewed and approved to not expire. The meeting is typically held the second Monday of each month. See approval letter for expiration date and continuing review due date.

However, if your research activities meet one of the following criteria, the Continuing Review Request may be approved by the IRB Chair in place of being reviewed at a convened meeting; therefore, the deadling for submission is two weeks prior to the study's expiration date:

1. The research is permanently closed to the enrollment of new subjects; all subjects have completed all research related interventions; and the research remains active only for long-term follow-up of subjects;
2. Where no subjects have been enrolled and no additional risks have been identified;
3. Where the remaining research activities are limited to data analysis; or
4. Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories for expedited approval do not apply, but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

Full Review projects are those which require review by the Board at a convened (monthly) meeting. Most projects do not require Full Review and can be approved by the IRB Chair or Administrator.

Review the following section to determine if your project requires Full Review.

An IRB application must be reviewed by the Board at a convened meeting (typically the second Monday of each month) if it includes activities involving the following:

• Prisoners
• Pregnant Women
• Fetuses
• Human in Vitro Fertilization
• Mentally Disabled Persons
• Microwaves or X-Rays
• General Anesthesia or Sedation
• Greater than Minimal Risks [than those anticipated under exempt & expedited research (e.g., questions about abuse, illegal activities)].

This list is not exhaustive. The final decision as to whether an application is reviewed by the Board at a convened meeting is that of the IRB Chair and/or Board.